Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press23610.17650/1726-9776-2011-7-3-65-69DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиHUMAN PLASMA PROTEOME MAPPING IN HEALTH AND CLEAR CELL CARCINOMA OF THE KIDNEYКАРТИРОВАНИЕ ПРОТЕОМА ПЛАЗМЫ КРОВИ ЧЕЛОВЕКА В НОРМЕ И ПРИ СВЕТЛОКЛЕТОЧНОМ РАКЕ ПОЧКИShevchenkoV. E.ШевченкоВ. Е.
Russian Federation
sergekov@mail.ruKovalevS. V.КовалевС. В.
Russian Federation
sergekov@mail.ruYurchenkoV. A.ЮрченкоВ. А.
Russian Federation
sergekov@mail.ruMatveevV. B.МатвеевВ. Б.
Russian Federation
sergekov@mail.ruZaridzeD. G.ЗаридзеД. Г.
Russian Federation
sergekov@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowРОНЦ им. Н.Н. Блохина РАМН, Москва300920117365690308201403082014https://oncourology.abvpress.ru/oncur/article/view/236

Plasma proteome from patients with renal cell carcinoma (RCC) and controls underwent mass spectrometric mapping. A total of 247 proteins were identified; the expression of 12 proteins of them increased on transition from the controls to patients with Stages I–II and III–IV RCC. There was decreased expression of 14 proteins in this series. Out of the 26 proteins showing a change in their expressions, 7 proteins belong to acute-phase ones, 3 proteins are associated with the intercellular matrix. These proteins can be potential markers for RCC.

Проведено масс-спектрометрическое картирование протеома плазмы крови больных почечно-клеточным раком (ПКР) и конт-рольной группы. Идентифицировано 247 белков, из них экспрессия 12 белков увеличивалась при переходе от данных контрольной группы к анализам больным с I−II и III−IV стадиями заболевания. Снижение экспрессии в этом ряду показывали 14 белков. Из 26 протеинов, показавших изменение экспрессии, 7 относятся к белкам острой фазы, 3 белка связаны с межклеточным матриксом. Данные белки могут быть потенциальными маркерами ПКР.

renal cell carcinomamass spectrometryproteomic markersпочечно-клеточный ракмасс-спектрометрияпротеомные маркеры1. Ljungberg B., Cowan N.C., Hanbury D.C. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398–406.Ljungberg B., Cowan N.C., Hanbury D.C. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398–406.2. Chow W.H., Dong L.M., Devesa S.S. Epidemiology and risk factors for kidney cancer. Nature Reviews Urology 2010;7:245−57.Chow W.H., Dong L.M., Devesa S.S. Epidemiology and risk factors for kidney cancer. Nature Reviews Urology 2010;7:245−57.3. Nickerson M.L., Jaeger E., Shi Y. et al. Improved identification of von Hippel-Lindau gene alternations in clear cell renal tumors. Clin Cancer Res 2008;14:4726–34.Nickerson M.L., Jaeger E., Shi Y. et al. Improved identification of von Hippel-Lindau gene alternations in clear cell renal tumors. Clin Cancer Res 2008;14:4726–34.4. Заридзе Д.Г. Профилактика рака. М.: ИМА-ПРЕСС, 2009.Заридзе Д.Г. Профилактика рака. М.: ИМА-ПРЕСС, 2009.5. Perroud B., Lee J., Valkova N. et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006;5:64−81.Perroud B., Lee J., Valkova N. et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006;5:64−81.6. Craven R.A., Stanley A.J., Hanrahan S. et al. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006;6:2853–64.Craven R.A., Stanley A.J., Hanrahan S. et al. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006;6:2853–64.7. Banks R.E., Craven R.A., Harnden P. et al. Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007;25:537–56.Banks R.E., Craven R.A., Harnden P. et al. Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007;25:537–56.8. Opatrná S., Chiangjong W., Korabecná M. et al. Plasma proteome profiling of von Hippel-Lindau disease after total and subtotal nephrectomy: a preliminary study. Clin Biochem 2010;43:142−9.Opatrná S., Chiangjong W., Korabecná M. et al. Plasma proteome profiling of von Hippel-Lindau disease after total and subtotal nephrectomy: a preliminary study. Clin Biochem 2010;43:142−9.9. Eichelberg C., Junker K., Ljungberg B. et al. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009;55:851–63.Eichelberg C., Junker K., Ljungberg B. et al. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009;55:851–63.10. Janech M.G., Raymond J.R., Arthur J.M. Proteomics in renal research. Am J Physiol Renal Physiol 2007;292:F501–F512.Janech M.G., Raymond J.R., Arthur J.M. Proteomics in renal research. Am J Physiol Renal Physiol 2007;292:F501–F512.11. http://www.chem.agilent.com/Library/usermanuals/Public/5969-1597.pdfhttp://www.chem.agilent.com/Library/usermanuals/Public/5969-1597.pdf12. http://www.chem.agilent.com/Library/usermanuals/Public/G2458-90003_SamplePrepGuide_online.pdf P. 67 77.http://www.chem.agilent.com/Library/usermanuals/Public/G2458-90003_SamplePrepGuide_online.pdf P. 67 77.13. Martosella J., Zolotarjova N., Liu H. et al. Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 2005;4:1522−37.Martosella J., Zolotarjova N., Liu H. et al. Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 2005;4:1522−37.14. www.hppp.orgwww.hppp.org15. Saito K., Tatokoro M., Fujii Y. et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009;55:1145–54.Saito K., Tatokoro M., Fujii Y. et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009;55:1145–54.16. Markiewski M.M., Lambris J.D. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 2009;30:286−92.Markiewski M.M., Lambris J.D. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 2009;30:286−92.17. Sadrzadeh S.M., Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 2004;121(Suppl):97−104.Sadrzadeh S.M., Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 2004;121(Suppl):97−104.18. Karpova M.A., Moshkovskii S.A., Toropygin I.Y. et al. Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives. J Proteomics 2010;73:537−51.Karpova M.A., Moshkovskii S.A., Toropygin I.Y. et al. Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives. J Proteomics 2010;73:537−51.19. Tolson J., Bogumil R., Brunst E. et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004;84:1220–1.Tolson J., Bogumil R., Brunst E. et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004;84:1220–1.20. Ramankulov A., Lein M., Johannsen M. et al. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 2008;269:85−92.Ramankulov A., Lein M., Johannsen M. et al. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 2008;269:85−92.21. Meyer H.A., Tulle A., Jung M. et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol 2009;55:669–78.Meyer H.A., Tulle A., Jung M. et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol 2009;55:669–78.22. Reichle A., Grassinger J., Bross K. et al. C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation. Biomark Insights 2007;1:87–98.Reichle A., Grassinger J., Bross K. et al. C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation. Biomark Insights 2007;1:87–98.23. Zeng Z., Hincapie M., Haab B.B. et al. The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A 2010;1217:3307−15.Zeng Z., Hincapie M., Haab B.B. et al. The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A 2010;1217:3307−15.24. Kreunin P., Zhao J., Rosser C. et al. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007;6:2631−9.Kreunin P., Zhao J., Rosser C. et al. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007;6:2631−9.25. Alvarez-Chaver P., Rodriguez-Piсeiro A.M., Rodriguez-Berrocal F.J. et al. Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Int J Biochem Cell Biol 2007;39:529−40.Alvarez-Chaver P., Rodriguez-Piсeiro A.M., Rodriguez-Berrocal F.J. et al. Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Int J Biochem Cell Biol 2007;39:529−40.26. Cervi D., Pak B., Venier Н.L. et al. Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4. BMC Cancer 2010;10:258-258.Cervi D., Pak B., Venier Н.L. et al. Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4. BMC Cancer 2010;10:258-258.27. Fiedler G.M., Leichtle A.B., Kase J. et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 2009;15:3812−9.Fiedler G.M., Leichtle A.B., Kase J. et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 2009;15:3812−9.28. Cervi D., Yip T.-T., Bhattacharya N. et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008;111:1201−7.Cervi D., Yip T.-T., Bhattacharya N. et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008;111:1201−7.29. Feldmann G., Mishra A., Hong S.M. et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 2010;70:4460−9.Feldmann G., Mishra A., Hong S.M. et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 2010;70:4460−9.30. Upadhyay A.K., Ajay A.K., Singh S. et al. Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Curr Cancer Drug Targets 2008;8:741−52.Upadhyay A.K., Ajay A.K., Singh S. et al. Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Curr Cancer Drug Targets 2008;8:741−52.31. Haiman M., Salvenmoser W., Scheiber K. et al. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int 2005;68:1130–6.Haiman M., Salvenmoser W., Scheiber K. et al. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int 2005;68:1130–6.32. Hall A.K. Amplification-independent overexpression of thymosin beta-10 mRNA in human renal cell carcinoma. Ren Fail 1994;16:243−54.Hall A.K. Amplification-independent overexpression of thymosin beta-10 mRNA in human renal cell carcinoma. Ren Fail 1994;16:243−54.33. Sparvero L.J., Asafu-Adjei D., Kang R. et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009;7:7−17.Sparvero L.J., Asafu-Adjei D., Kang R. et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009;7:7−17.34. Liang X., Huuskonen J., Hajivandi M. et al. Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines. Proteomics 2009;9:182−93.Liang X., Huuskonen J., Hajivandi M. et al. Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines. Proteomics 2009;9:182−93.35. Forstenberger G., Senn E., Morant R. et al. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. Breast 2006;15:64−8.Forstenberger G., Senn E., Morant R. et al. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. Breast 2006;15:64−8.